Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 20;397(10279):1057-1058.
doi: 10.1016/S0140-6736(21)00501-8. Epub 2021 Feb 25.

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty  1 , Ashley D Otter  2 , Thomas A Treibel  1 , Áine McKnight  3 , Daniel M Altmann  4 , Timothy Brooks  2 , Mahdad Noursadeghi  5 , Rosemary J Boyton  6 , Amanda Semper  2 , James C Moon  1
Affiliations

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al. Lancet. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Serological response to one dose of the BNT162b2 mRNA COVID-19 vaccine in individuals with and without laboratory-confirmed previous SARS-CoV-2 infection SARS-CoV-2 anti-S antibody titres in individuals with no previous infection are similar to titres in individuals who have had a mild SARS-CoV-2 infection. Anti-S titres in those with previous SARS-CoV-2 infection are more than 140-fold greater than at time of peak infection. Statistical analysis was by unpaired two-tailed t test. U=unit. NS=non-significant.
See this image and copyright information in PMC

References

    1. Joint Committee on Vaccination and Immunisation Optimising the COVID-19 vaccination programme for maximum short-term impact. Jan 26, 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-...
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Eng J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. - PMC - PubMed
    1. Treibel TA, Manisty C, Burton M, et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet. 2020;395:1608–1610. - PMC - PubMed
    1. Reynolds CJ, Swadling L, Gibbons JM, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020;5 - PMC - PubMed